Showing results (111-120 of 127) with videos related to
Sort By:
Pageof 13
Molecular Cell|September 23, 2021
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gapsMariana Paes Dias, Vivek Tripathi, Ingrid van der Heijden, et al.Cancer Research|March 8, 2012
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumorsSven Rottenberg, Marieke A Vollebergh, Bas de Hoon, et al.NPJ Precision Oncology|January 10, 2024
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomicsAlberto Valdeolivas, Bettina Amberg, Nicolas Giroud, et al.Nature Cell Biology|June 2, 2026
Nucleophagy removes cytotoxic trapped PARP1Gwendoline Hoslett, Sara Tribble, Pauline Lascaux, et al.Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.Toxicologic Pathology|February 11, 2025
Points to Consider From the ESTP Pathology 2.0 Working Group: Overview on Spatial Omics Technologies Supporting Drug Discovery and DevelopmentKerstin Hahn, Bettina Amberg, Josep M Monné Rodriguez, et al.Cell Reports|May 20, 2023
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsJinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.Nature|July 23, 2016
Replication fork stability confers chemoresistance in BRCA-deficient cellsArnab Ray Chaudhuri, Elsa Callen, Xia Ding, et al.NPJ Precision Oncology|July 11, 2026
Aurora kinase A is a synthetic lethal target in FANCA-deficient cancersDilara Akhoundova, Martín González-Fernández, Aavash Baral, et al.Science (New York, N.Y.)|February 19, 2026
The oncogenome of the domestic catBailey A Francis, Latasha Ludwig, Chang He, et al.Pageof 13